Prescription Drug Information: Tacrolimus (Page 8 of 12)

12.3 Pharmacokinetics

Tacrolimus activity is primarily due to the parent drug. The pharmacokinetic parameters (mean±S.D.) of tacrolimus have been determined following oral (PO) administration in healthy volunteers, and in kidney transplant, liver transplant, and heart transplant patients (Table 14).

Table 14. Pharmacokinetics Parameters (mean±S.D.) of Tacrolimus in Healthy Volunteers and Patients

*
a) not applicable
a) not applicable
b) AUC0-120 ;
§
c) AUC0-72
d) Corrected for individual bioavailability
#
d) Corrected for individual bioavailability
Þ
a) not applicable
ß
a) not applicable
à
e) AUC0-inf ;
è
f) not available
ð
f) not available
ø
f) not available
ý
e) AUC0-inf ;
£
f) not available
¥
f) not available
Œ
f) not available
œ
a) not applicable
Ɖ
a) not applicable
A
e) AUC0-inf ;
B
e) AUC0-inf ;
C
f) not available
D
f) not available
E
f) not available
F
a) not applicable
G
a) not applicable
H
g) AUC0-t
I
f) not available
J
h) Determined after the first dose
K
i) Median [range]
L
j) AUC0-12
M
a) not applicable
N
f) not available
O
f) not available
P
h) Determined after the first dose
Q
i) Median [range]
R
j) AUC0-12
S
a) not applicable
T
f) not available
U
f) not available
Population N Route (Dose) Parameters
Cmax (ng/mL) Tmax (hr) AUC (ng•hr/mL) t1/2 (hr) CI (L/hr/kg) V (L/kg)
Healthy Volunteers 8 IV (0.025 mg/kg/4hr) * 598± 125 34.2 ± 7.7 0.040 ± 0.009 1.91 ± 0.31
16 PO (5 mg) 29.7 ± 7.2 1.6 ± 0.7 243§± 73 34.8 ± 11.4 0.041 ±0.008 1.94# ± 0.53
Kidney Transplant Patients 26 IV (0.02 mg/kg/12 hr) Þ ß 294 e± 262 18.8 ± 16.7 0.083 ± 0.050 1.41 ± 0.66
PO (0.2 mg/kg/day) 19.2 ± 10.3 3.0 203à± 42 è ð ø
PO (0.3 mg/kg/day) 24.2 ± 15.8 1.5 288ý± 93 £ ¥ Œ
Liver Transplant Patients 17 IV (0.05 mg/kg/12 hr) œ Ɖ 3300A± 2130 11.7 ± 3.9 0.053 ± 0.017 0.85 ± 0.30
PO (0.3 mg/kg/day) 68.5 ± 30.0 2.3 ± 1.5 519B± 179 C D E
Heart Transplant Patients 11 IV (0.01 mg/kg/day as a continuous infusion) F G 954H± 334 23.6 ± 9.22 0.051 ± 0.015 I
11 PO (0.075 mg/kg/day)J 14.7 ± 7.79 2.1 [0.5-6.0]K 82.7L± 63.2 M N O
14 PO (0.15 mg/kg/day)P 24.5 ± 13.7 1.5 [0.4-4.0]Q 142R± 116 S T U

Due to intersubject variability in tacrolimus pharmacokinetics, individualization of dosing regimen is necessary for optimal therapy [see Dosage and Administration (2.6)]. Pharmacokinetic data indicate that whole blood concentrations rather than plasma concentrations serve as the more appropriate sampling compartment to describe tacrolimus pharmacokinetics.

Absorption

Absorption of tacrolimus from the gastrointestinal tract after oral administration is incomplete and variable. The absolute bioavailability of tacrolimus was 17±10% in adult kidney transplant patients (N=26), 22±6% in adult liver transplant patients (N=17), and 18±5% in healthy volunteers (N=16).

A single dose trial conducted in 32 healthy volunteers established the bioequivalence of the 1 mg and 5 mg capsules. Another single dose trial in 32 healthy volunteers established the bioequivalence of the 0.5 mg and 1 mg capsules. Tacrolimus maximum blood concentrations (Cmax ) and area under the curve (AUC) appeared to increase in a doseproportional fashion in 18 fasted healthy volunteers receiving a single oral dose of 3, 7, and 10 mg.

In 18 kidney transplant patients, tacrolimus trough concentrations from 3 to 30 ng/mL measured at 10-12 hours post-dose (Cmin ) correlated well with the AUC (correlation coefficient 0.93). In 24 liver transplant patients over a concentration range of 10 to 60 ng/mL, the correlation coefficient was 0.94.

In 25 heart transplant patients over a concentration range of 2 to 24 ng/mL, the correlation coefficient was 0.89 after an oral dose of 0.075 or 0.15 mg/kg/day at steady-state.

Food Effects

The rate and extent of tacrolimus absorption were greatest under fasted conditions. The presence and composition of food decreased both the rate and extent of tacrolimus absorption when administered to 15 healthy volunteers.

The effect was most pronounced with a high-fat meal (848 kcal, 46% fat): mean AUC and Cmax were decreased 37% and 77%, respectively; Tmax was lengthened 5-fold. A high-carbohydrate meal (668 kcal, 85% carbohydrate) decreased mean AUC and mean Cmax by 28% and 65%, respectively.

In healthy volunteers (N=16), the time of the meal also affected tacrolimus bioavailability. When given immediately following the meal, mean Cmax was reduced 71%, and mean AUC was reduced 39%, relative to the fasted condition. When administered 1.5 hours following the meal, mean Cmax was reduced 63%, and mean AUC was reduced 39%, relative to the fasted condition.

In 11 liver transplant patients, Tacrolimus Capsules USP administered 15 minutes after a high fat (400 kcal, 34% fat) breakfast, resulted in decreased AUC (27±18%) and Cmax (50±19%), as compared to a fasted state.

Tacrolimus Capsules USP should be taken consistently every day either with or without food because the presence and composition of food decreases the bioavailability of tacrolimus [see Dosage and Administration (2.5)].

Distribution

The plasma protein binding of tacrolimus is approximately 99% and is independent of concentration over a range of 5-50 ng/mL. Tacrolimus is bound mainly to albumin and alpha-1-acid glycoprotein, and has a high level of association with erythrocytes. The distribution of tacrolimus between whole blood and plasma depends on several factors, such as hematocrit, temperature at the time of plasma separation, drug concentration, and plasma protein concentration. In a U.S. trial, the ratio of whole blood concentration to plasma concentration averaged 35 (range 12 to 67).

RxDrugLabels.com provides trustworthy package insert and label information about marketed prescription drugs as submitted by manufacturers to the U.S. Food and Drug Administration. Package information is not reviewed or updated separately by RxDrugLabels.com. Every individual prescription drug label and package insert entry contains a unique identifier which can be used to secure further details directly from the U.S. National Institutes of Health and/or the FDA.

As a leading independent provider of trustworthy medication information, we source our database directly from the FDA's central repository of drug labels and package inserts under the Structured Product Labeling standard. RxDrugLabels.com provides the full prescription-only subset of the FDA's repository. Medication information provided here is not intended as a substitute for direct consultation with a qualified health professional.

Terms of Use | Copyright © 2024. All Rights Reserved.